Who are Autologous Apheresis PRP Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Autologous platelets rich plasma, prolotherapy solution of 20% dextrose, Regenerative tissue matrix, SRP + Injectable Platelet-Rich Fibrin, ACP, hyaluronic Acid + platelet-rich plasma.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/autologous-apheresis-prp-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Autologous Apheresis PRP Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous Apheresis PRP Injection (Autologous Apheresis PRP Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Regenerative medicine. Area: Orthopedics, Wound care.

phase 2 Regenerative medicine Orthopedics, Wound care Biologic Live · refreshed every 30 min

Target snapshot

Autologous Apheresis PRP Injection (Autologous Apheresis PRP Injection) — zhang li. Autologous Apheresis PRP Injection is a regenerative medicine treatment that uses a patient's own platelet-rich plasma to stimulate healing and tissue repair.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Autologous Apheresis PRP Injection TARGET	Autologous Apheresis PRP Injection	zhang li	phase 2	Regenerative medicine
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product
prolotherapy solution of 20% dextrose	prolotherapy solution of 20% dextrose	Hadassah Medical Organization	marketed	Regenerative medicine agent
Regenerative tissue matrix	Regenerative tissue matrix	University of Louisville	marketed	Regenerative medicine product / Tissue engineering scaffold
SRP + Injectable Platelet-Rich Fibrin	SRP + Injectable Platelet-Rich Fibrin	University of Belgrade	marketed	Regenerative medicine / Periodontal therapy
ACP	ACP	Istituto Ortopedico Rizzoli	marketed	Cell therapy / Regenerative medicine product
hyaluronic Acid + platelet-rich plasma	hyaluronic Acid + platelet-rich plasma	University of Milan	marketed	Regenerative medicine / Biologic combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Regenerative medicine class)

Amarantus BioScience Holdings, Inc. · 1 drug in this class
CUTISS AG · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
zhang li · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Autologous Apheresis PRP Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-apheresis-prp-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab